Monoclonal Antibody Development

MBS has the experience and technical expertise to meet the most challenging monoclonal antibody development goals.  Our Ph.D. led hybridoma technical team works with customers from the development of a comprehensive project plan, through hybridoma and working assay development.  MBS scientists manage, analyze and communicate data, so you can make timely, responsive strategy decisions along the way.

Phase 1: Initiation

  • Hybridoma Initiation Checklist:  To develop the best application specific antibody, communication is paramount.  The Hybridoma Initiation Checklist is the customer’s first opportunity to provide MBS with the details necessary to strategize an optimal approach.
  • Technical Meeting: Open access to MBS technical resources and personnel begins with a conference call with the Hybridoma Development team to customize the project for success.

Phase 2: Immunization

With a success rate of over 85%, the MBS Rapid Immunization Protocol enables a fusion on day 28 of the project.  This protocol ensures the fastest possible outcome for monoclonal antibody development.

  • Immunization, Day 0: 3-5 mice are immunized with antigen. 2-3 mgs of antigen is required.  1 mg of additional counter-screening reagents required, if applicable.
  • Titer determination, Day 20: Titer is determined by indirect ELISA, additional assays can be performed.  A mouse or rat with adequate titer (1:31K) is selected for fusion.  If  titer is not reached  by day 20, additional boosts may be administered.
  • Fusion boost, Day 24
  • Additional immunization strategies include; subtractive immunizations (immunosupression), DNA immunizations, and cellular immunizations.

Phase 3: Fusion featuring MultiPure Technology

  • Fusion, Day 28:  The fused spleen(s) is plated across 10-20 plates (96 wells each).  Fusion size is variable and is at the discretion of the customer.
  • Primary Screening, Day 38-42: Fusion product supernatants are screened by  ELISA (primary screen) against the immunogen, along with any necessary counter-screens.
  • ELISA options include: sandwich, cell based, bridging, blocking/inhibition, and indirect.
  • Scale-Up and Cryopreservation, approx. 2 weeks: Depending on the amount of antibody required for  customer evaluation, selected positive fusion products are scaled-up to generate  3-5 mLs of  supernatant, or alternatively 15 mLs of overgrown supernatant.  Supernatant from the 15 mL volume samples can be purified using the MBS developed MultiPure technology.  Two vials of each selected fusion product are cryopreserved at this stage.
  • Secondary Screening:  Selected fusion products are screened a second time after scale up, by ELISA,  to confirm stability and ensure active antibody secretion.  A small percentage of fusion products can lose productivity during the scale-up phase and the secondary screen is important to confirm productivity before selecting fusion products for subcloning.
  • Once 15 ml supernatant samples are available, the customer can opt to use our novel MultiPure system to generate purified antibody.  Doing so allows early insight into antibody performance, relative affinities, and even matched pair capabilities.  With the use of MultiPure, subcloning choices can be made with real, final application data saving both time and money.
  • Alternative fusion strategy available – B-cell separation.
  • A fusion product(s) is selected for subcloning.

Read more about MultiPure Process

Phase 4: Subcloning

  • Subcloning,:   The selected fusion product(s) is subcloned by limiting dilution.
  • Subclone Screening: Screening by ELISA is performed against the immunogen and any necessary counter-screening agents.
  • Subclone, Scale-Up, and Cryopreservation: Approximately  2 weeks, depending on the amount of antibody required for  customer evaluation, selected subclones are scaled-up to generate  3-5 mLs of  supernatant, or alternatively 15 mLs of overgrown supernatant.  Supernatant from the 15 mL volume samples can be purified using the MBS developed MultiPure technology.  Two vials of each selected subclone are cryopreserved at this stage.

Phase 5: Antibody Production

Our premium monoclonal antibody development service is complimented by being a trusted partner in cGMP bulk antibody production.

  • In Vivo Production:  Antibody can be produced in vivo via mouse ascites.  Ascites production typically takes 6 weeks with an additional 1 week added for purification.  On average, cell lines will produce 3-5 mLs of ascites per mouse with an antibody concentration of 3-5 mg/mL.
  • In Vitro Production: In vitro production is performed in roller bottles.  A 1 liter production takes approximately 3-4 weeks with an additional 1 week for purification. Production levels range from 20-50 mg/L depending on the cell line.
  • Yields are cell line dependent and are not guaranteed.

Contact us today for more information 207-797-5454 or [email protected]

Polyclonal Antibody Development

Click Here to Learn More about Antibody Production Services